Stock 6610 TWI BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials TWi Biotechnology, Inc.

Equities

6610

TW0006610009

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 29/05/2024 BST 		5-day change 1st Jan Change
12.2 TWD -0.81% Intraday chart for TWi Biotechnology, Inc. -2.40% -12.86%
04-09 TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,349 590.1 1,015 1,089 1,007 1,229
Enterprise Value (EV) 1 861.6 206.3 810.1 870 849.5 913.4
P/E ratio -10.8 x -5.29 x -9.96 x -70.2 x -13.1 x -6 x
Yield - - - - - -
Capitalization / Revenue 52.2 x 61.1 x 815 x 16.4 x - -
EV / Revenue 33.3 x 21.3 x 650 x 13.1 x - -
EV / EBITDA -8.02 x -1.95 x -9.05 x -129 x -10.3 x -5.63 x
EV / FCF -11.2 x -3.57 x -33.2 x -9.78 x -21.1 x -13.3 x
FCF Yield -8.89% -28% -3.01% -10.2% -4.75% -7.5%
Price to Book 2.66 x 1.49 x 3.45 x 3.91 x 4.89 x 3.6 x
Nbr of stocks (in thousands) 67,434 67,434 67,434 67,434 67,834 87,794
Reference price 2 20.00 8.750 15.05 16.15 14.85 14.00
Announcement Date 03/04/19 22/04/20 27/04/21 27/04/22 26/04/23 09/04/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 25.84 9.664 1.246 66.4 - -
EBITDA 1 -107.4 -106 -89.56 -6.719 -82.34 -162.3
EBIT 1 -115.3 -113.9 -98.56 -15.3 -90.18 -169.6
Operating Margin -446.36% -1,179.01% -7,909.95% -23.04% - -
Earnings before Tax (EBT) 1 -112.5 -111.5 -100.5 -15.3 -76.18 -170.7
Net income 1 -112.5 -111.5 -101.9 -15.3 -76.18 -170.7
Net margin -435.48% -1,154.01% -8,174.8% -23.04% - -
EPS 2 -1.860 -1.654 -1.510 -0.2300 -1.130 -2.332
Free Cash Flow 1 -76.61 -57.82 -24.39 -88.91 -40.34 -68.48
FCF margin -296.5% -598.3% -1,957.32% -133.9% - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 03/04/19 22/04/20 27/04/21 27/04/22 26/04/23 09/04/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 487 384 205 219 158 316
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -76.6 -57.8 -24.4 -88.9 -40.3 -68.5
ROE (net income / shareholders' equity) -30.3% -24.7% -29.5% -5.34% -31.4% -62.4%
ROA (Net income/ Total Assets) -17.7% -14.7% -15.1% -2.74% -20.7% -33.6%
Assets 1 637.3 760.4 674.8 558.3 368.6 508.3
Book Value Per Share 2 7.530 5.870 4.360 4.130 3.040 3.880
Cash Flow per Share 2 2.740 0.8500 0.9500 2.800 2.360 1.730
Capex 1 2.13 0.15 - 0.23 - -
Capex / Sales 8.24% 1.58% - 0.34% - -
Announcement Date 03/04/19 22/04/20 27/04/21 27/04/22 26/04/23 09/04/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TWI BIOTECHNOLOGY, INC. Stock TWi Biotechnology, Inc.
-12.86% 33.02M
MODERNA, INC. Stock Moderna, Inc.
+53.14% 58.06B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-4.53% 40.53B
LONZA GROUP AG Stock Lonza Group AG
+37.32% 38.99B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.54% 26.7B
CELLTRION, INC. Stock Celltrion, Inc.
-12.01% 26.56B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.47% 18.98B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+1.50% 12.17B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+23.68% 12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.13% 11.92B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6610 Stock
  4. Financials TWi Biotechnology, Inc.